An antibacterial drug is referred to as an antimicrobial agent interfering with the growth and reproduction of bacteria that cause numerous mild to severe infections in humans and animals. Antibacterial drugs either kill or inhibit their growth. These agents possess bactericidal activity which target various parts of bacterial physiology such as protein synthesis, cell wall synthesis, nucleic acid synthesis and permeability of cell membrane, and therefore help in treating infections. Antibacterial drugs are being in use since the discovery of the first antibacterial in the form of penicillin in 1928, and presently a wide range of antibacterials in several formulations are commercially available and used for the treatment of various indications like pneumonia, tuberculosis, tetanus, diphtheria, diarrhea, legionellosis and other diseases.
Download exclusive Sample of this report:
High prevalence of infectious diseases, government support and increased research and development activities, and product differentiation through various methods drive the antibacterial drugs market. However, rise in drug-resistant species, launch of generics, and upcoming patent expirations are anticipated to restrict the growth of the global market through 2023.The report offers a pipeline analysis of some of the key antibacterial drugs such as Zempia, Actoxumab/Aezlotoxumab, RHB-105, SYM-1219, Ozenoxacin, SPL7013, Cadazolid, Arikace, Surotomycin, Eravacycline, Carbavance, Delamanid, Omadacycline, Solithromycin, Ciprofloxacin/Fluocinolone Acetonide, Delafloxacin, and Plazomycin.
Based on drug class, the antibacterial drugs market is categorized into B-lactams, sulfonamides, macrolides, aminoglycosides, tetracyclines, quinolones/fluoroquinolones, phenicols, and miscellaneous antibacterials. Accounting for a share of 57.70% in the overall antibacterial drugs market in 2014, B-lactams dominated the scene. However, this drug class is anticipated to witness a drop in market share by 2023. The miscellaneous antibacterials category, on the other hand, is projected to develop at the highest growth rate from 2015 to 2023.
View exclusive Global strategic Business report :
Geographically, the global antibacterial drugs market is segmented into North America, Asia Pacific, Latin America, Europe, and Rest of the World. Asia Pacific presently dominates the overall market and is also projected to witness the fastest growth over the duration of the forecast period. The Asia Pacific antibacterial drugs market is fueled by rising incidences of bacterial infections such as tuberculosis and MRSA, presence of large number of manufacturers of active pharmaceutical ingredient and generic drugs, rising purchasing power of the domestic population, expanding geriatric population, and developing healthcare infrastructure.
North America, followed by Europe, is the second largest regional market for antibacterial drugs in terms of revenue. These regions are anticipated to witness slow growth over the next seven years owing to stringent regulatory requirements, shortened product lifecycle, and generic infiltration.
The research report identifies and assesses the performance of the key players operating in the global antibacterial drugs market. These players are profiled based on attributes such as company and financial overview, business strategies, product portfolio, and recent developments. The companies featured in the antibacterial drugs market report are GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Sanofi, Johnson & Johnson, Bristol-Myers Squibb Company, AstraZeneca plc, Allergan plc (Actavis Plc), Bayer AG, and Eli Lilly and Company.